IP35: Bladder Cancer: Epidemiology & Evaluation I
Saturday, May 16, 2026 9:30 AM to 11:30 AM · 2 hr. (America/New_York)
147A
Poster and Podium Sessions
Oncology: Bladder
Saturday, May 16
IP35-01: Predictors of adherence to intravesical Bacillus Calmette-Guerin (BCG) induction schedules for the treatment of early bladder cancer among U.S. Medicare beneficiaries from 2004 to 2019
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-02: Real-world outcomes of BCG-retreatment after BCG failure in patients with papillary only high-risk non-muscle-invasive bladder cancer: a Retrospective Study in the American Urological Association’s Quality Registry
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-03: Comparative Effectiveness of Intravesical Chemotherapy Agents versus Bacillus Calmette-Guérin in High-Risk Non-Muscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-04: Prospective Evaluation of the Cxbladder-Triage Urinary Biomarker for Risk Stratification of Hematuria Patients in an Australian Tertiary Referral Centre
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-05: Artificial intelligence diagnostics for bladder tumor identification and grade prediction depend on narrow band imaging cystoscopy.
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-06: Performance of Bladder EpiCheck in the detection of recurrent high grade bladder cancer: A real world experience from a large community center
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-07: Diverging Survival Paths in Pure Bladder SCC: Insights into Tumor Biology and Management
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-08: Clinical Patterns and Pathogenesis of Bladder Leiomyoma: A Multicenter Observational Study
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-09: Hepatitis and the Risk of Bladder Cancer: A Nationwide Population-Based Study from South Korea
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-10: From Risk Scores to Probabilities: Calibrated Machine Learning Improves Bladder Cancer Recurrence Prediction over EORTC
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-11: Influence of GLP1 Receptor Agonist on Bladder Cancer Incidence and Overall Survival, A Propensity Score Matched Analysis Using the OptumLabs Data Warehouse
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-12: Complete TURBT versus mpMRI/cystoscopic biopsy alone in the diagnosis of MIBC.
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-13: USE OF A MULTIMODAL PREDICTIVE MODEL ASSOCIATED WITH MASSON'S TRICHROME STAINING AND CLINICAL VARIABLES AS PREDICTORS OF MUSCLE INVASION IN BLADDER CANCER.
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-14: Diagnostic Utility of Pre-Cystectomy Bladder Magnetic Resonance Imaging
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-15: Molecular characterization and a showcase clinical study on treatment de-escalation for luminal favorable muscle-invasive bladder cancer
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-16: Germline Mutations and Demographic Differences in Pure Urothelial Cancer
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-17: Age-Associated Germline Variations in Bladder Cancer: Insights from All of Us Whole-Genome Sequencing
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-18: Familial Clustering of Bladder Cancer Across Three Generations: Whole-Genome Analysis Identifies Novel Germline Candidates Beyond Known Hereditary Syndromes
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-19: A Population-Level Assessment of Urologists’ Microhematuria Evaluation Practices following the 2020 AUA Guideline Recommendation Changes: Results from the 2024 AUA Census
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
Samuel Gold · Memorial Sloan Kettering Cancer Center
IP35-20: Comparative Performance and Economic Impact of the 2020 vs 2025 AUA Microscopic Hematuria Guidelines
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-21: Guideline Adherence for Hematuria Evaluation in the Real World: Evidence from 1.9 million Patients in Epic COSMOS
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-22: Optimizing Risk Stratification for Urothelial Neoplasms in Patients with Microscopic Hematuria with a Novel Risk Calculator Versus the AUA 2020/2025 Guidelines
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-23: ARE TURBT PATHOLOGY OVERREADS NECESSARY? A DESCRIPTIVE REVIEW OF PATHOLOGIC CONCORDANCE FOR REFERRED BLADDER CANCER PATIENTS OVER A 12-YEAR PERIOD
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-24: Frequency and Determinants of Reproductive Organ Involvement in Female Patients Undergoing Radical Cystectomy for Bladder Cancer
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-25: Impact of Area Deprivation on Cancer-Specific Mortality in Non–Muscle-Invasive Bladder Cancer: Insights From a Statewide Cohort
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-26: Defining the Epidemiologic Landscape of Young-Onset Bladder Cancer: A SEER Population-Based Analysis
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-27: Air, Water, and the Bladder: Environmental, Behavioral, and Socioeconomic Correlates of Female-Predominant Bladder-Cancer Mortality
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-28: The association of smoking history and disease characteristics and recurrence among NMIBC
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
IP35-29: Feasibility of a Computer Vision Model to Identify Bladder Cancer during Cystoscopy
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
Zorawar Singh · Northwell Health, Northshore/Long Island Jewish
IP35-30: Optimizing Bladder Cancer Detection: Effects of Prompt Engineering on Multimodal LLM-Assisted Cystoscopy
Saturday, May 16, 2026 9:30 AM to 11:30 AM
147A
Registered attendees
KS
Kristian Stensland
Assistant ProfessorUniversity of Michigan